These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 21959288)

  • 41. Multivariate equivalence tests for use in pharmaceutical development.
    Hoffelder T; Gössl R; Wellek S
    J Biopharm Stat; 2015; 25(3):417-37. PubMed ID: 24896319
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The right medicines--just not enough of them.
    Honig PK
    Clin Pharmacol Ther; 2012 Mar; 91(3):369-72. PubMed ID: 22343809
    [No Abstract]   [Full Text] [Related]  

  • 43. Small molecule compound logistics outsourcing--going beyond the "thought experiment".
    Ramsay DL; Kwasnoski JD; Caldwell GW
    Curr Top Med Chem; 2012; 12(11):1298-308. PubMed ID: 22571792
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Accelerated drug discovery by rapid candidate drug identification.
    Bergström F; Lindmark B
    Drug Discov Today; 2019 Jun; 24(6):1237-1241. PubMed ID: 30946980
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Extension of quality-by-design concept to the early development phase of pharmaceutical R&D processes.
    Csóka I; Pallagi E; Paál TL
    Drug Discov Today; 2018 Jul; 23(7):1340-1343. PubMed ID: 29601866
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Medicinal chemistry in drug discovery in big pharma: past, present and future.
    Campbell IB; Macdonald SJF; Procopiou PA
    Drug Discov Today; 2018 Feb; 23(2):219-234. PubMed ID: 29031621
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FAF-Drugs3: a web server for compound property calculation and chemical library design.
    Lagorce D; Sperandio O; Baell JB; Miteva MA; Villoutreix BO
    Nucleic Acids Res; 2015 Jul; 43(W1):W200-7. PubMed ID: 25883137
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Informing the Selection of Screening Hit Series with in Silico Absorption, Distribution, Metabolism, Excretion, and Toxicity Profiles.
    Sanders JM; Beshore DC; Culberson JC; Fells JI; Imbriglio JE; Gunaydin H; Haidle AM; Labroli M; Mattioni BE; Sciammetta N; Shipe WD; Sheridan RP; Suen LM; Verras A; Walji A; Joshi EM; Bueters T
    J Med Chem; 2017 Aug; 60(16):6771-6780. PubMed ID: 28418656
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictive QSAR modeling for the successful predictions of the ADMET properties of candidate drug molecules.
    Khan MT; Sylte I
    Curr Drug Discov Technol; 2007 Oct; 4(3):141-9. PubMed ID: 17985997
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Knowledge-based chemoinformatic approaches to drug discovery.
    Ghose AK; Herbertz T; Salvino JM; Mallamo JP
    Drug Discov Today; 2006 Dec; 11(23-24):1107-14. PubMed ID: 17129830
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overview of determination of biopharmaceutical properties for development candidate selection.
    Yazdanian M
    Curr Protoc Pharmacol; 2013 Mar; Chapter 9():Unit9.17. PubMed ID: 23456615
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The practice of pre-marketing safety assessment in drug development.
    Chuang-Stein C; Xia HA
    J Biopharm Stat; 2013; 23(1):3-25. PubMed ID: 23331218
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction of Oral Bioavailability in Rats: Transferring Insights from in Vitro Correlations to (Deep) Machine Learning Models Using in Silico Model Outputs and Chemical Structure Parameters.
    Schneckener S; Grimbs S; Hey J; Menz S; Osmers M; Schaper S; Hillisch A; Göller AH
    J Chem Inf Model; 2019 Nov; 59(11):4893-4905. PubMed ID: 31714067
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery pharmaceutics--challenges and opportunities.
    Chen XQ; Antman MD; Gesenberg C; Gudmundsson OS
    AAPS J; 2006 Jun; 8(2):E402-8. PubMed ID: 16796392
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the "Metabolites in Safety Testing" Regulatory Guidance.
    Schadt S; Bister B; Chowdhury SK; Funk C; Hop CECA; Humphreys WG; Igarashi F; James AD; Kagan M; Khojasteh SC; Nedderman ANR; Prakash C; Runge F; Scheible H; Spracklin DK; Swart P; Tse S; Yuan J; Obach RS
    Drug Metab Dispos; 2018 Jun; 46(6):865-878. PubMed ID: 29487142
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of selection bias on the evaluation of clusters of chemical compounds in the drug discovery process.
    Alonso A; Milanzi E; Molenberghs G; Buyck C; Bijnens L
    Pharm Stat; 2015; 14(2):129-38. PubMed ID: 25420717
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Learning lessons from drugs that have recently entered the market.
    Teague SJ
    Drug Discov Today; 2011 May; 16(9-10):398-411. PubMed ID: 21414418
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Follow-on drugs: how far should chemists look?
    Giordanetto F; Boström J; Tyrchan C
    Drug Discov Today; 2011 Aug; 16(15-16):722-32. PubMed ID: 21658467
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Approaches for multi-gram scale isolation of enantiomers for drug discovery.
    Rossi D; Tarantino M; Rossino G; Rui M; Juza M; Collina S
    Expert Opin Drug Discov; 2017 Dec; 12(12):1253-1269. PubMed ID: 28971706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.